Payment overview · 2025
General Payments
$913.20
44 reported records · 12 companies
Healthcare provider profile · identity verified
Michael G Gilhooley, MD
Allopathic & Osteopathic Physicians|Internal Medicine · SCRANTON, PA · NPI 1093751034
Verified facts
What the public records show
CMS Open Payments records show Michael G Gilhooley, MD received $913.20 in general payments during 2025 across 44 reported records.
Novo Nordisk Inc accounted for 40.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic, Rexulti, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Synthroid by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 129 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 129 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 95 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Nuedexta by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 624 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $371.20 | 40.6% | 12 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $147.04 | 16.1% | 8 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $85.73 | 9.4% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $60.81 | 6.7% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $54.17 | 5.9% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $45.85 | 5.0% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $44.49 | 4.9% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $29.40 | 3.2% | 2 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $28.52 | 3.1% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $16.47 | 1.8% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $15.43 | 1.7% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.09 | 1.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $913.20 | 44 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $191.53 | 11 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $189.34 | 6 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $181.86 | 6 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $59.70 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $56.86 | 5 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $54.17 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $48.25 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $46.96 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $46.96 | 3 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $37.48 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $29.40 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $29.40 | 2 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $28.52 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $22.20 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $16.47 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $16.47 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $15.43 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $14.09 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 129 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 95 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 38 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
35 | 12 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
129 | 28 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
129 | 28 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
67 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
95 | 17 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
624 | 65 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Eliquis | Apixaban | 624 | 65 |
| Alprazolam | Alprazolam | 623 | 94 |
| Atorvastatin Calcium | Atorvastatin Calcium | 616 | 152 |
| Lisinopril | Lisinopril | 504 | 122 |
| Furosemide | Furosemide | 449 | 79 |
| Amlodipine Besylate | Amlodipine Besylate | 427 | 102 |
| Levothyroxine Sodium | Levothyroxine Sodium | 426 | 92 |
| Metoprolol Tartrate | Metoprolol Tartrate | 415 | 64 |
| Metoprolol Succinate | Metoprolol Succinate | 412 | 90 |
| Metformin Hcl | Metformin Hcl | 375 | 73 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 375 | 84 |
| Simvastatin | Simvastatin | 359 | 94 |
| Gabapentin | Gabapentin | 293 | 51 |
| Omeprazole | Omeprazole | 293 | 92 |
| Potassium Chloride | Potassium Chloride | 275 | 47 |
| Donepezil Hcl | Donepezil Hcl | 258 | 42 |
| Tamsulosin Hcl | Tamsulosin Hcl | 256 | 63 |
| Pantoprazole Sodium | Pantoprazole Sodium | 232 | 67 |
| Losartan Potassium | Losartan Potassium | 226 | 70 |
| Tramadol Hcl | Tramadol Hcl | 202 | 54 |
| Zolpidem Tartrate | Zolpidem Tartrate | 176 | 37 |
| Warfarin Sodium | Warfarin Sodium | 172 | 19 |
| Lorazepam | Lorazepam | 171 | 28 |
| Duloxetine Hcl | Duloxetine Hcl | 161 | 28 |
| Quetiapine Fumarate | Quetiapine Fumarate | 157 | 22 |
| Citalopram Hbr | Citalopram Hydrobromide | 155 | 47 |
| Mirtazapine | Mirtazapine | 155 | 22 |
| Sertraline Hcl | Sertraline Hcl | 153 | 30 |
| Escitalopram Oxalate | Escitalopram Oxalate | 140 | 37 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 134 | 25 |
| Famotidine | Famotidine | 131 | 24 |
| Divalproex Sodium | Divalproex Sodium | 130 | 20 |
| Jardiance | Empagliflozin | 129 | 28 |
| Topiramate | Topiramate | 127 | suppressed |
| Xarelto | Rivaroxaban | 120 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 116 | 29 |
| Azithromycin | Azithromycin | 99 | 74 |
| Finasteride | Finasteride | 98 | 17 |
| Ozempic | Semaglutide | 95 | 17 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 91 | 19 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 86 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 85 | 17 |
| Allopurinol | Allopurinol | 84 | 16 |
| Hydrochlorothiazide | Hydrochlorothiazide | 83 | 27 |
| Trazodone Hcl | Trazodone Hcl | 81 | 20 |
| Memantine Hcl | Memantine Hcl | 78 | 20 |
| Cephalexin | Cephalexin | 76 | 50 |
| Carvedilol | Carvedilol | 75 | 14 |
| Prednisone | Prednisone | 75 | 21 |
| Meloxicam | Meloxicam | 74 | 14 |
| Buspirone Hcl | Buspirone Hcl | 72 | 18 |
| Fluticasone Propionate | Fluticasone Propionate | 71 | 18 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 70 | 34 |
| Sucralfate | Sucralfate | 68 | suppressed |
| Trulicity | Dulaglutide | 67 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 66 | 17 |
| Montelukast Sodium | Montelukast Sodium | 62 | suppressed |
| Torsemide | Torsemide | 61 | 16 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 60 | 45 |
| Aripiprazole | Aripiprazole | 58 | suppressed |
| Spironolactone | Spironolactone | 55 | 12 |
| Clonazepam | Clonazepam | 53 | 12 |
| Januvia | Sitagliptin Phosphate | 51 | 13 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 51 | suppressed |
| Olanzapine | Olanzapine | 48 | 14 |
| Pregabalin | Pregabalin | 47 | 11 |
| Lactulose | Lactulose | 45 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 45 | suppressed |
| Irbesartan | Irbesartan | 44 | 12 |
| Risperidone | Risperidone | 44 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 43 | 20 |
| Felodipine Er | Felodipine | 42 | 13 |
| Baclofen | Baclofen | 41 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 41 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 39 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 39 | suppressed |
| Glimepiride | Glimepiride | 39 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 39 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 39 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 38 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 38 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 37 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 37 | 14 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 36 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 36 | 17 |
| Pioglitazone Hcl | Pioglitazone Hcl | 36 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 35 | suppressed |
| Synthroid | Levothyroxine Sodium | 35 | 12 |
| Methylprednisolone | Methylprednisolone | 34 | 30 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 33 | 26 |
| Diclofenac Sodium | Diclofenac Sodium | 33 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 33 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 33 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 32 | 17 |
| Ropinirole Hcl | Ropinirole Hcl | 32 | suppressed |
| Ezetimibe | Ezetimibe | 31 | suppressed |
| Ramipril | Ramipril | 30 | suppressed |
| Tradjenta | Linagliptin | 30 | suppressed |
| Glipizide Er | Glipizide | 29 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 29 | suppressed |
| Novolog | Insulin Aspart | 29 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 29 | suppressed |
| Bupropion Xl | Bupropion Hcl | 28 | suppressed |
| Clomipramine Hcl | Clomipramine Hcl | 28 | suppressed |
| Glipizide | Glipizide | 28 | suppressed |
| Levetiracetam | Levetiracetam | 28 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 27 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 27 | 12 |
| Ibuprofen | Ibuprofen | 27 | suppressed |
| Levofloxacin | Levofloxacin | 27 | 20 |
| Midodrine Hcl | Midodrine Hcl | 26 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 26 | suppressed |
| Amoxicillin | Amoxicillin | 25 | 17 |
| Dicyclomine Hcl | Dicyclomine Hcl | 25 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 25 | suppressed |
| Restasis | Cyclosporine | 25 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 25 | 14 |
| Xifaxan | Rifaximin | 25 | suppressed |
| Atenolol | Atenolol | 24 | suppressed |
| Nadolol | Nadolol | 24 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 24 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 23 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 23 | suppressed |
| Valsartan | Valsartan | 23 | suppressed |
| Rexulti | Brexpiprazole | 22 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 21 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 20 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 19 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 19 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 19 | suppressed |
| Myrbetriq | Mirabegron | 19 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 18 | suppressed |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 18 | suppressed |
| Dutasteride | Dutasteride | 18 | suppressed |
| Eszopiclone | Eszopiclone | 18 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 18 | suppressed |
| Klor-Con M20 | Potassium Chloride | 18 | suppressed |
| Latanoprost | Latanoprost | 18 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 18 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 18 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 18 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 18 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 17 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 17 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 17 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 17 | suppressed |
| Repatha Sureclick | Evolocumab | 17 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 17 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 16 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 16 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 16 | suppressed |
| Fenofibrate | Fenofibrate | 16 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 15 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 15 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 15 | suppressed |
| Entresto | Sacubitril/Valsartan | 15 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 15 | suppressed |
| Methimazole | Methimazole | 15 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 15 | 12 |
| Sevelamer Hcl | Sevelamer Hcl | 15 | suppressed |
| Testosterone | Testosterone | 15 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 14 | suppressed |
| Fluconazole | Fluconazole | 14 | 11 |
| Ibandronate Sodium | Ibandronate Sodium | 14 | suppressed |
| Naproxen | Naproxen | 14 | suppressed |
| Rybelsus | Semaglutide | 14 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Metolazone | Metolazone | 13 | suppressed |
| Mexiletine Hcl | Mexiletine Hcl | 13 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 13 | suppressed |
| Amantadine | Amantadine Hcl | 12 | suppressed |
| Lyumjev | Insulin Lispro-Aabc | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 12 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 11 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 11 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 11 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 11 | suppressed |
| Paliperidone Er | Paliperidone | 11 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $913.20 · 44 records | Novo Nordisk Inc | AUSTEDO XR, Cologuard Collection Kit, JARDIANCE, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, QULIPTA, REPATHA, REXULTI, Rybelsus, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, UBRELVY, VOQUEZNA, Wegovy, ZAVZPRET, ZEPBOUND | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error